ATE429931T1 - Zusammensetzungen zur hemmung der proliferation und infiltration von gehirntumorzellen durch expression der ampa-typ glutamat-rezeptor- untereinheit - Google Patents
Zusammensetzungen zur hemmung der proliferation und infiltration von gehirntumorzellen durch expression der ampa-typ glutamat-rezeptor- untereinheitInfo
- Publication number
- ATE429931T1 ATE429931T1 AT03784615T AT03784615T ATE429931T1 AT E429931 T1 ATE429931 T1 AT E429931T1 AT 03784615 T AT03784615 T AT 03784615T AT 03784615 T AT03784615 T AT 03784615T AT E429931 T1 ATE429931 T1 AT E429931T1
- Authority
- AT
- Austria
- Prior art keywords
- tumor cells
- brain tumor
- glutamate receptor
- ampa
- infiltration
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title abstract 10
- 210000004881 tumor cell Anatomy 0.000 title abstract 10
- 102000018899 Glutamate Receptors Human genes 0.000 title abstract 5
- 108010027915 Glutamate Receptors Proteins 0.000 title abstract 5
- 230000035755 proliferation Effects 0.000 title abstract 5
- 230000008595 infiltration Effects 0.000 title 1
- 238000001764 infiltration Methods 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009545 invasion Effects 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- 230000035699 permeability Effects 0.000 abstract 2
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002232086A JP4175846B2 (ja) | 2002-08-08 | 2002-08-08 | Ampa型グルタミン酸受容体サブユニットの発現による脳腫瘍細胞の増殖と浸潤の抑制 |
PCT/JP2003/010143 WO2004014433A1 (ja) | 2002-08-08 | 2003-08-08 | Ampa型グルタミン酸受容体サブユニットの発現による脳腫瘍細胞の増殖と浸潤の抑制 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE429931T1 true ATE429931T1 (de) | 2009-05-15 |
Family
ID=31711765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03784615T ATE429931T1 (de) | 2002-08-08 | 2003-08-08 | Zusammensetzungen zur hemmung der proliferation und infiltration von gehirntumorzellen durch expression der ampa-typ glutamat-rezeptor- untereinheit |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060128645A1 (de) |
EP (1) | EP1552852B1 (de) |
JP (1) | JP4175846B2 (de) |
AT (1) | ATE429931T1 (de) |
CA (1) | CA2494063C (de) |
DE (1) | DE60327449D1 (de) |
ES (1) | ES2324780T3 (de) |
WO (1) | WO2004014433A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04009496A (es) | 2002-03-29 | 2005-01-25 | Yamanouchi Pharma Co Ltd | Remedio para glioblastoma. |
GB0416730D0 (en) | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
GB0507298D0 (en) * | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
US20100311838A1 (en) | 2009-05-29 | 2010-12-09 | Pipkin James D | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
JP6371063B2 (ja) * | 2013-01-30 | 2018-08-08 | 国立大学法人 岡山大学 | 悪性腫瘍の検査方法および抗腫瘍剤 |
WO2020023800A1 (en) * | 2018-07-27 | 2020-01-30 | With Great Power, Llc | Clinical methods and pharmaceutical compositions employing ampa receptor antagonists to treat glioblastoma and other cancers |
CN111269939A (zh) * | 2019-07-16 | 2020-06-12 | 湖南大学深圳研究院 | 稳定表达AMPA受体GluR1/GluR2细胞株及其构建方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE265528T1 (de) * | 1989-10-27 | 2004-05-15 | Salk Inst For Biological Studi | Rezeptorverbindungen von glutamin und herstellung |
-
2002
- 2002-08-08 JP JP2002232086A patent/JP4175846B2/ja not_active Expired - Fee Related
-
2003
- 2003-08-08 CA CA2494063A patent/CA2494063C/en not_active Expired - Fee Related
- 2003-08-08 ES ES03784615T patent/ES2324780T3/es not_active Expired - Lifetime
- 2003-08-08 DE DE60327449T patent/DE60327449D1/de not_active Expired - Lifetime
- 2003-08-08 EP EP03784615A patent/EP1552852B1/de not_active Expired - Lifetime
- 2003-08-08 US US10/524,046 patent/US20060128645A1/en not_active Abandoned
- 2003-08-08 AT AT03784615T patent/ATE429931T1/de not_active IP Right Cessation
- 2003-08-08 WO PCT/JP2003/010143 patent/WO2004014433A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20060128645A1 (en) | 2006-06-15 |
DE60327449D1 (de) | 2009-06-10 |
JP4175846B2 (ja) | 2008-11-05 |
EP1552852A1 (de) | 2005-07-13 |
ES2324780T3 (es) | 2009-08-14 |
JP2004067627A (ja) | 2004-03-04 |
CA2494063C (en) | 2011-03-15 |
EP1552852B1 (de) | 2009-04-29 |
CA2494063A1 (en) | 2004-02-19 |
EP1552852A4 (de) | 2006-11-29 |
WO2004014433A1 (ja) | 2004-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sander et al. | Histamine H3 receptor antagonists go to clinics | |
Amargós-Bosch et al. | Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex | |
DE60335743D1 (de) | Verbindungen und verfahren zur erhöhung der neurogenese | |
CY1118096T1 (el) | Ρυθμιστες υποδοχεα οπιοειδους | |
DK1525200T3 (da) | 2-(3-aminoaryl)amino-4-aryl-thiazoler til sygdomsbehandling | |
WO2006064375A2 (en) | Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases | |
DE602007010914D1 (de) | Substituierte phenylpiperidinderivate als melanocortin-4-rezeptormodulatoren | |
DE602005024279D1 (de) | 5-substituierte-2-phenylaminobenzamide als mek-inhibitoren | |
BR0116113A (pt) | Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas | |
DK1263752T3 (da) | LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf | |
ATE429931T1 (de) | Zusammensetzungen zur hemmung der proliferation und infiltration von gehirntumorzellen durch expression der ampa-typ glutamat-rezeptor- untereinheit | |
SG156625A1 (en) | Method for measuring resistance or sensitivity to docetaxel | |
EA200601378A1 (ru) | Гидроизоиндолиновые антагонисты рецептора тахикинина | |
ATE530541T1 (de) | Substituierte heteroarylpiperidinderivate als modulatoren des melanocortin-4-rezeptors | |
DE602005027322D1 (de) | Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall | |
DE60327652D1 (de) | Diarylureidoderivate und deren medizinische verwendung | |
DE602005009512D1 (de) | 3-((hetero)arylsulfonyl)-8-ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns | |
ATE452130T1 (de) | 1-(hetero)aryl-3-aminopyrrolidinderivate zur verwendung als antagonisten des mglur3-rezeptors | |
MX2009004314A (es) | Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos. | |
Bayarri et al. | Melatonin binding sites in the brain of European sea bass (Dicentrarchus labrax) | |
ATE282625T1 (de) | Gaba-c-rezeptor-antagonisten zur stimulation des erinnerungsvermögens | |
DE602004013427D1 (de) | Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen | |
ATE425791T1 (de) | Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten | |
ATE386519T1 (de) | Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren | |
WO2007098393A3 (en) | Compounds and methods for treating diseases with trpv4 channel receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |